{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T18:44:40Z","timestamp":1782585880519,"version":"3.54.5"},"reference-count":136,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Just over thirty years is the span of a generation. It is also the time that has passed since the discovery of the gene responsible for cystic fibrosis. Today, it is safe to say that this discovery has revolutionized our understanding, research perspectives, and management of this disease, which was, thirty years ago, a pediatric condition with a grim prognosis. The aim of this review is to present the advances that science and medicine have brought to our understanding of the pathophysiology of the disease and its management, which in many ways, epitomizes modern molecular genetic research. Since the discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in 1989, modeling the CFTR protein, deciphering its function as an ion channel, and identifying its molecular partners have led to numerous therapeutic advances. The most significant advancement in this field has been the discovery of protein modulators that can target its membrane localization and chloride channel activity. However, further progress is needed to ensure that all patients can benefit from a therapy tailored to their mutations, with the primary challenge being the development of treatments for mutations leading to a complete absence of the protein. The present review delves into the history of the multifaceted world of CF, covering main historical facts, current landscape, clinical management, emerging therapies, patient perspectives, and the importance of ongoing research, bridging science and medicine in the fight against the disease.<\/jats:p>","DOI":"10.3390\/ijms25179599","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T09:57:47Z","timestamp":1725443867000},"page":"9599","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cystic Fibrosis: A Journey through Time and Hope"],"prefix":"10.3390","volume":"25","author":[{"given":"Pascal","family":"Trouv\u00e9","sequence":"first","affiliation":[{"name":"Univ Brest, Inserm, EFS, UMR 1078, 22 Avenue Camille Desmoulins, F-29200 Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Saint Pierre","sequence":"additional","affiliation":[{"name":"Univ Brest, Inserm, EFS, UMR 1078, 22 Avenue Camille Desmoulins, F-29200 Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2325-0710","authenticated-orcid":false,"given":"Claude","family":"F\u00e9rec","sequence":"additional","affiliation":[{"name":"Univ Brest, Inserm, EFS, UMR 1078, 22 Avenue Camille Desmoulins, F-29200 Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1126\/science.2570460","article-title":"Identification of the cystic fibrosis gene: Genetic analysis","volume":"245","author":"Kerem","year":"1989","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1126\/science.2997931","article-title":"Cystic Fibrosis Locus Defined by a Genetically Linked Polymorphic DNA Marker","volume":"230","author":"Tsui","year":"1985","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1126\/science.2772657","article-title":"Identification of the cystic fibrosis gene: Chromosome walking and jumping","volume":"245","author":"Rommens","year":"1989","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"key":"ref_5","first-page":"547","article-title":"Cystic fibrosis is no longer an important cause of childhood death in the UK","volume":"90","author":"Dodge","year":"2005","journal-title":"Arch. Dis. Child."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/archpedi.155.5.621","article-title":"Metabolic Diseases: Foundations of Clinical Management, Genetics and Pathology","volume":"155","author":"Farrell","year":"2001","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"ref_7","unstructured":"Valle, D.L., Antonarakis, S., Ballabio, A., Beaudet, A.L., and Mitchell, G.A. (2019). Cystic Fibrosis. The Online Metabolic and Molecular Bases of Inherited Disease, McGraw-Hill Education."},{"key":"ref_8","first-page":"903","article-title":"Darmverschluss durch Eingedticktes Meconium Pankreatitis","volume":"16","author":"Landsteiner","year":"1905","journal-title":"Zentralbl. Allg. Pathol."},{"key":"ref_9","first-page":"753","article-title":"Das coeliakiesyndrom bei angeborener zysticher pankreasfibromatose und bronchiektasien","volume":"86","author":"Fanconi","year":"1936","journal-title":"Wien. Med. Wschr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archpedi.1938.01980140114013","article-title":"Cystic fibrosis of the pancreas and its relation to celiac disease: A clinical and pathologic study","volume":"56","author":"Andersen","year":"1938","journal-title":"Am. J. Dis. Child."},{"key":"ref_11","unstructured":"(2024, August 01). Farber: Some Organic Digestive Disturbances in Early Life\u2013Google Scholar. Available online: https:\/\/scholar.google.com\/scholar_lookup?hl=en&volume=44&publication_year=1945&pages=587-594&journal=J.+Mich.+State.+Med.+Soc.&author=S.+FARBER&title=Some+organic+digestive+disturbances+in+early+life."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/archpedi.1946.02020300069004","article-title":"Celiac syndrome; genetics of cystic fibrosis of the pancreas, with a consideration of etiology","volume":"72","author":"Andersen","year":"1946","journal-title":"Am. J. Dis. Child."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1542\/peds.12.5.549","article-title":"Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas; Clinical significance and relationship to the disease","volume":"12","author":"Darling","year":"1953","journal-title":"Pediatrics"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1542\/peds.23.3.545","article-title":"A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis","volume":"23","author":"Gibson","year":"1959","journal-title":"Pediatrics"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1203\/00006450-196711000-00002","article-title":"A Sodium Transport Inhibitory Factor in the Saliva of Patients with Cystic Fibrosis of the Pancreas","volume":"1","author":"Mangos","year":"1967","journal-title":"Pediatr. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e24997","DOI":"10.4161\/tisb.24997","article-title":"Barrier function of airway tract epithelium","volume":"1","author":"Ganesan","year":"2013","journal-title":"Tissue Barriers"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1136\/thoraxjnl-2016-209279","article-title":"The lower airway microbiota in early cystic fibrosis lung disease: A longitudinal analysis","volume":"72","author":"Frayman","year":"2017","journal-title":"Thorax"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMra1813799","article-title":"Muco-Obstructive Lung Diseases","volume":"380","author":"Boucher","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1172\/JCI73469","article-title":"Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure","volume":"124","author":"Henderson","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1378\/chest.129.1.118","article-title":"Mucus properties in children with primary ciliary dyskinesia: Comparison with cystic fibrosis","volume":"129","author":"Bush","year":"2006","journal-title":"Chest"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1007\/s00018-015-1946-7","article-title":"Airway hydration and COPD","volume":"72","author":"Ghosh","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1172\/JCI110892","article-title":"Intracellular chloride activities in canine tracheal epithelium. Direct evidence for sodium-coupled intracellular chloride accumulation in a chloride-secreting epithelium","volume":"71","author":"Welsh","year":"1983","journal-title":"J. Clin. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/jappl.1980.49.5.905","article-title":"Fluid transport across the canine tracheal epithelium","volume":"49","author":"Welsh","year":"1980","journal-title":"J. Appl. Physiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6167","DOI":"10.1073\/pnas.82.18.6167","article-title":"Cystic fibrosis decreases the apical membrane chloride permeability of mon-olayers cultured from cells of tracheal epithelium","volume":"82","author":"Widdicombe","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/301421a0","article-title":"Chloride impermeability in cystic fibrosis","volume":"301","author":"Quinton","year":"1983","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM198305193082002","article-title":"Higher Bioelectric Potentials Due to Decreased Chloride Absorption in the Sweat Glands of Patients with Cystic Fibrosis","volume":"308","author":"Quinton","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1126\/science.6308769","article-title":"Abnormal Ion Permeation Through Cystic Fibrosis Respiratory Epithelium","volume":"221","author":"Knowles","year":"1983","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1172\/JCI110894","article-title":"Relative ion permeability of normal and cystic fibrosis nasal epithelium","volume":"71","author":"Knowles","year":"1983","journal-title":"J. Clin. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1113\/jphysiol.1988.sp017322","article-title":"Evidence for reduced Cl\u2212 and increased Na+ permeability in cystic fibrosis human primary cell cultures","volume":"405","author":"Boucher","year":"1988","journal-title":"J. Physiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1172\/JCI112812","article-title":"Abnormal apical cell membrane in cystic fibrosis respiratory epithelium. An in vitro electrophysiologic analysis","volume":"79","author":"Cotton","year":"1987","journal-title":"J. Clin. Investig."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1096\/fasebj.2.10.2838365","article-title":"Altered intestinal chloride transport in cystic fibrosis","volume":"2","author":"Berschneider","year":"1988","journal-title":"FASEB J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1172\/JCI112708","article-title":"Na+ transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation","volume":"78","author":"Boucher","year":"1986","journal-title":"J. Clin. Investig."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1126\/science.1712984","article-title":"Demonstration That CFTR Is a Chloride Channel by Alteration of Its Anion Selectivity","volume":"253","author":"Anderson","year":"1991","journal-title":"Science"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/0092-8674(91)90072-7","article-title":"Nucleoside triphosphates are required to open the CFTR chloride channel","volume":"67","author":"Anderson","year":"1991","journal-title":"Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6003","DOI":"10.1073\/pnas.88.14.6003","article-title":"Calcium and cAMP activate different chloride channels in the apical membrane of normal and cystic fibrosis epithelia","volume":"88","author":"Anderson","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"C251","DOI":"10.1152\/ajpcell.1992.262.1.C251","article-title":"cAMP-activated chloride conductance in the colonic cell line, Caco-2","volume":"262","author":"Bear","year":"1992","journal-title":"Am. J. Physiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1126\/science.7543698","article-title":"CFTR as a cAMP-dependent regulator of sodium channels","volume":"269","author":"Stutts","year":"1995","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"12742","DOI":"10.1016\/S0021-9258(18)42339-3","article-title":"Phosphorylation of the cystic fibrosis transmembrane conductance regulator","volume":"267","author":"Picciotto","year":"1992","journal-title":"J. Biol. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1096\/fasebj.4.10.2197151","article-title":"Cystic fibrosis: A disease in electrolyte transport","volume":"4","author":"Quinton","year":"1990","journal-title":"FASEB J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJM198112173052502","article-title":"Increased Bioelectric Potential Difference across Respiratory Epithelia in Cystic Fibrosis","volume":"305","author":"Knowles","year":"1981","journal-title":"N. Engl. J. Med."},{"key":"ref_41","first-page":"484","article-title":"Measurements of nasal transepithelial electric potential differences in normal human subjects in vivo","volume":"124","author":"Knowles","year":"1981","journal-title":"Am. Rev. Respir. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/367463a0","article-title":"Amiloride-sensitive epithelial Na+ channel is made of three homologous subunits","volume":"367","author":"Canessa","year":"1994","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"24379","DOI":"10.1016\/S0021-9258(19)51094-8","article-title":"Membrane topology of the amiloride-sensitive epithelial sodium channel","volume":"269","author":"Snyder","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0014-5793(96)01414-7","article-title":"Inhibition of epithelial Na+ currents by intracellular domains of the cystic fibrosis transmembrane conductance regulator","volume":"400","author":"Kunzelmann","year":"1997","journal-title":"FEBS Lett."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"C657","DOI":"10.1152\/ajpcell.1997.272.2.C657","article-title":"cAMP stimulates CFTR-like Cl\u2212 channels and inhibits amiloride-sensitive Na+ channels in mouse CCD cells","volume":"272","author":"Letz","year":"1997","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1039\/B810471A","article-title":"Assessment of the CFTR and ENaC association","volume":"5","author":"Berdiev","year":"2008","journal-title":"Mol. Biosyst."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/embo-reports\/kve045","article-title":"Non-specific activation of the epithelial sodium channel by the CFTR chloride channel","volume":"2","author":"Nagel","year":"2001","journal-title":"EMBO Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1113\/jphysiol.2004.079046","article-title":"CFTR fails to inhibit the epithelial sodium channel ENaC expressed in Xenopus laevis oocytes","volume":"564","author":"Nagel","year":"2005","journal-title":"J. Physiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0092-8674(90)90148-8","article-title":"Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis","volume":"63","author":"Cheng","year":"1990","journal-title":"Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1146\/annurev.ge.29.120195.004021","article-title":"Cystic Fibrosis: Genotypic and Phenotypic Variations","volume":"29","author":"Zielenski","year":"1995","journal-title":"Annu. Rev. Genet."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"21592","DOI":"10.1016\/S0021-9258(20)80582-1","article-title":"The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells","volume":"268","author":"Lukacs","year":"1993","journal-title":"J. Biol. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/s41431-018-0234-z","article-title":"Estimating the age of p.(Phe508del) with family studies of geographically distinct European populations and the early spread of cystic fibrosis","volume":"26","author":"Farrell","year":"2018","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/ng0692-188","article-title":"Detection of over 98% cystic fibrosis mutations in a Celtic population","volume":"1","author":"Audrezet","year":"1992","journal-title":"Nat. Genet."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41586-023-05854-7","article-title":"CFTR function, pathology and pharmacology at single-molecule resolution","volume":"616","author":"Levring","year":"2023","journal-title":"Nature"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1073\/pnas.0303411101","article-title":"Stimulatory and inhibitory protein kinase C consensus sequences regulate the cystic fibrosis transmembrane conductance regulator","volume":"101","author":"Chappe","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"C1366","DOI":"10.1152\/ajpcell.00034.2008","article-title":"PKC phosphorylation modulates PKA-dependent binding of the R domain to other domains of CFTR","volume":"295","author":"Seavilleklein","year":"2008","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0005-2736(99)00163-7","article-title":"Influence of phosphorylation by protein kinase A on CFTR at the cell surface and endoplasmic reticulum","volume":"1461","author":"Seibert","year":"1999","journal-title":"Biochim. Biophys. Acta (BBA)\u2014Biomembr."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1513\/pats.2306011","article-title":"The Cystic Fibrosis Transmembrane Regulator Forms Macromolecular Complexes with PDZ Domain Scaffold Proteins","volume":"1","author":"Guggino","year":"2004","journal-title":"Proc. Am. Thorac. Soc."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Murabito, A., Bhatt, J., and Ghigo, A. (2023). It Takes Two to Tango! Protein-Protein Interactions behind cAMP-Mediated CFTR Regulation. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310538"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.pharmthera.2005.04.004","article-title":"Macromolecular complexes of cystic fibrosis transmembrane conductance regulator and its interacting partners","volume":"108","author":"Li","year":"2005","journal-title":"Pharmacol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Estabrooks, S., and Brodsky, J.L. (2020). Regulation of CFTR Biogenesis by the Proteostatic Network and Pharmacological Modulators. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21020452"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Simon, S., Aissat, A., Degrugillier, F., Simonneau, B., Fanen, P., and Arrigo, A.-P. (2021). Small Hsps as Therapeutic Targets of Cystic Fibrosis Transmembrane Conductance Regulator Protein. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22084252"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"041","DOI":"10.1385\/JMN:23:1-2:041","article-title":"CFTR and Chaperones: Processing and Degradation","volume":"23","author":"Amaral","year":"2004","journal-title":"J. Mol. Neurosci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2000946","DOI":"10.1183\/13993003.00946-2020","article-title":"ENaC inhibition in cystic fibrosis: Potential role in the new era of CFTR modulator therapies","volume":"56","author":"Mall","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nm1028","article-title":"Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice","volume":"10","author":"Mall","year":"2004","journal-title":"Nat. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0014-5793(96)00079-8","article-title":"Wild type but not deltaF508 CFTR inhibits Na+ conductance when coexpressed in Xenopus oocytes","volume":"381","author":"Mall","year":"1996","journal-title":"FEBS Lett."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s00018-014-1749-2","article-title":"Full-open and closed CFTR channels, with lateral tunnels from the cytoplasm and an alternative position of the F508 region, as revealed by molecular dynamics","volume":"72","author":"Mornon","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.coph.2017.09.006","article-title":"The implications of CFTR structural studies for cystic fibrosis drug development","volume":"34","author":"Callebaut","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00018-016-2385-9","article-title":"Molecular modelling and molecular dynamics of CFTR","volume":"74","author":"Callebaut","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrg3849","article-title":"Cystic fibrosis genetics: From molecular understanding to clinical application","volume":"16","author":"Cutting","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/0140-6736(90)92566-Z","article-title":"Independent genetic determinants of pancreatic and pulmonary status in cystic fibrosis","volume":"336","author":"Santis","year":"1990","journal-title":"Lancet"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1046\/j.1469-1809.2003.00028.x","article-title":"The Phenotypic Consequences of CFTR Mutations","volume":"67","author":"Rowntree","year":"2003","journal-title":"Ann. Hum. Genet."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/humu.23276","article-title":"CFTR-France, a national relational patient database for sharing genetic and phenotypic data associated with rare CFTR variants","volume":"38","author":"Claustres","year":"2017","journal-title":"Hum. Mutat."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1183\/09031936.00196314","article-title":"Future trends in cystic fibrosis demography in 34 European countries","volume":"46","author":"Burgel","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"M\u00e9sin\u00e8le, J., Ruffin, M., Guillot, L., and Corvol, H. (2022). Modifier Factors of Cystic Fibrosis Phenotypes: A Focus on Modifier Genes. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232214205"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Trouv\u00e9, P., G\u00e9nin, E., and F\u00e9rec, C. (2017). In silico search for modifier genes associated with pancreatic and liver disease in Cystic Fibrosis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0173822"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jcf.2024.03.008","article-title":"ECFS standards of care on CFTR-related disorders: Identification and care of the disorders","volume":"23","author":"Simmonds","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"eS25","DOI":"10.1016\/S0929-693X(20)30047-6","article-title":"Genetic diagnosis in practice: From cystic fibrosis to CFTR-related disorders","volume":"27","author":"Pagin","year":"2020","journal-title":"Arch. Pediatr."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"a009480","DOI":"10.1101\/cshperspect.a009480","article-title":"Assessing the Disease-Liability of Mutations in CFTR","volume":"2","author":"Ferec","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/0140-6736(90)92066-Q","article-title":"Abnormal distribution of CF delta F508 allele in azoospermic men with congenital aplasia of epididymis and vas deferens","volume":"336","author":"Dumur","year":"1990","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1001\/jama.1992.03480130110034","article-title":"Congenital bilateral absence of the vas deferens. A primarily genital form of cystic fibrosis","volume":"267","author":"Anguiano","year":"1992","journal-title":"JAMA"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJM199506013322204","article-title":"Mutations in the Cystic Fibrosis Gene in Patients with Congenital Absence of the Vas Deferens","volume":"332","author":"Casals","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_83","first-page":"272","article-title":"Is congenital bilateral absence of vas deferens a primary form of cystic fibrosis? Analyses of the CFTR gene in 67 patients","volume":"56","author":"Mercier","year":"1995","journal-title":"Am. J. Hum. Genet."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJM199809033391002","article-title":"Relation between Mutations of the Cystic Fibrosis Gene and Idiopathic Pancreatitis","volume":"339","author":"Cohn","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Masson, E., Chen, J.-M., Audr\u00e9zet, M.-P., Cooper, D.N., and F\u00e9rec, C. (2013). A Conservative Assessment of the Major Genetic Causes of Idiopathic Chronic Pancreatitis: Data from a Comprehensive Analysis of PRSS1, SPINK1, CTRC and CFTR Genes in 253 Young French Patients. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0073522"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1146\/annurev-genom-082908-150009","article-title":"Chronic Pancreatitis: Genetics and Pathogenesis","volume":"10","author":"Chen","year":"2009","journal-title":"Annu. Rev. Genom. Hum. Genet."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1073\/pnas.1914912117","article-title":"Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions","volume":"117","author":"Miller","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/dc09-0586","article-title":"Cystic fibrosis-related diabetes: Current trends in prevalence, incidence, and mortality","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S1569-1993(11)60014-3","article-title":"Recommendations for the classification of diseases as CFTR-related disorders","volume":"10","author":"Bombieri","year":"2011","journal-title":"J. Cyst. Fibros."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.107.1.1","article-title":"Early Diagnosis of Cystic Fibrosis Through Neonatal Screening Prevents Severe Malnutrition and Improves Long-Term Growth","volume":"107","author":"Farrell","year":"2001","journal-title":"Pediatrics"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(00)02652-0","article-title":"Neonatal screening for cystic fibrosis in Brittany, France: Assessment of 10 years\u2019 experience and impact on prenatal diagnosis","volume":"356","author":"Scotet","year":"2000","journal-title":"Lancet"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Scotet, V., L\u2019hostis, C., and F\u00e9rec, C. (2020). The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery. Genes, 11.","DOI":"10.3390\/genes11060589"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.rmr.2015.12.001","article-title":"Demographic growth and targeted therapies: The changing face of cystic fibrosis","volume":"33","author":"Fajac","year":"2016","journal-title":"Rev. Mal. Respir."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/j.lpm.2017.04.012","article-title":"The changing epidemiology and demography of cystic fibrosis","volume":"46","author":"Stephenson","year":"2017","journal-title":"Presse Med."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Farrell, P.M., Rock, M.J., and Baker, M.W. (2020). The Impact of the CFTR Gene Discovery on Cystic Fibrosis Diagnosis, Counseling, and Preventive Therapy. Genes, 11.","DOI":"10.3390\/genes11040401"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jcf.2006.05.008","article-title":"A survey of newborn screening for cystic fibrosis in Europe","volume":"6","author":"Southern","year":"2007","journal-title":"J. Cyst. Fibros."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"eS4","DOI":"10.1016\/S0929-693X(20)30043-9","article-title":"Genetics of cystic fibrosis: Basics","volume":"27","author":"Scotet","year":"2020","journal-title":"Arch. Pediatr."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Scotet, V., Gutierrez, H., and Farrell, P.M. (2020). Newborn Screening for CF across the Globe-Where Is It Worthwhile?. Int. J. Neonatal Screen., 6.","DOI":"10.3390\/ijns6010018"},{"key":"ref_99","unstructured":"(2024, August 01). ECFS Patient Registry. Available online: https:\/\/www.ecfs.eu\/sites\/default\/files\/general-content-images\/working-groups\/ecfs-patient-registry\/ECFSPR_Report_2019_v1_23Dec2021.pdf."},{"key":"ref_100","first-page":"17","article-title":"Celiac syndrome; chemotherapy in infections of the respiratory tract associated with cystic fibrosis of the pancreas; observations with penicillin and drugs of the sulfonamide group, with special reference to penicillin aerosol","volume":"72","author":"Andersen","year":"1946","journal-title":"Am. J. Dis. Child. 1911"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/ptj\/39.1.24","article-title":"Physical Therapy in the Treatment of Cystic Fibrosis","volume":"39","author":"Doyle","year":"1959","journal-title":"Phys. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0031-3955(16)33069-3","article-title":"Cystic Fibrosis: A Not-So-Fatal Disease","volume":"21","author":"Crozier","year":"1974","journal-title":"Pediatr. Clin. N. Am."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0140-6736(79)90825-0","article-title":"Dried-Blood Spot Screening for Cystic Fibrosis in the Newborn","volume":"313","author":"Crossle","year":"1979","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(81)90588-2","article-title":"Aerosol Carbenicillin and Gentamicin Treatment of Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis","volume":"318","author":"Hodson","year":"1981","journal-title":"Lancet"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/adc.63.5.512","article-title":"Home intravenous antibiotic treatment in cystic fibrosis","volume":"63","author":"Gilbert","year":"1988","journal-title":"Arch. Dis. Child."},{"key":"ref_106","first-page":"459","article-title":"Heart-Lung Transplantation for Cystic-Fibrosis and Subsequent Domino Heart-Transplantation","volume":"9","author":"Yacoub","year":"1990","journal-title":"J. Heart Transplant."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/j.1460-2075.1992.tb05125.x","article-title":"Transfection of wild-type CFTR into cystic fibrosis lymphocytes restores chloride conductance at G1 of the cell cycle","volume":"11","author":"Krauss","year":"1992","journal-title":"EMBO J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-med-012017-043332","article-title":"Entering the Modern Era of Gene Therapy","volume":"70","author":"Anguela","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/biot.201400841","article-title":"Synthetic vectors for gene delivery: An overview of their evolution depending on routes of administration","volume":"10","author":"Belmadi","year":"2015","journal-title":"Biotechnol. J."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1126\/science.adk9428","article-title":"In vivo editing of lung stem cells for durable gene correction in mice","volume":"384","author":"Sun","year":"2024","journal-title":"Science"},{"key":"ref_111","first-page":"CD012040","article-title":"Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis","volume":"3","author":"Aslam","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jcf.2019.12.001","article-title":"Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action","volume":"19","author":"Laselva","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S2213-2600(14)70100-6","article-title":"Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial","volume":"2","author":"Kerem","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"McElroy, S.P., Nomura, T., Torrie, L.S., Warbrick, E., Gartner, U., Wood, G., and McLean, W.H.I. (2013). A Lack of Premature Termination Codon Read-Through Efficacy of PTC124 (Ataluren) in a Diverse Array of Reporter Assays. PLoS Biol., 11.","DOI":"10.1371\/journal.pbio.1001593"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00109-002-0363-1","article-title":"Aminoglycoside suppression of a premature stop mutation in a Cftr\u2212\/\u2212 mouse carrying a human CFTR-G542X transgene","volume":"80","author":"Du","year":"2002","journal-title":"J. Mol. Med. Berl. Ger."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nm0496-467","article-title":"Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations","volume":"2","author":"Howard","year":"1996","journal-title":"Nat. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e2020599118","DOI":"10.1073\/pnas.2020599118","article-title":"Ataluren and aminoglycosides stimulate read-through of non-sense codons by orthogonal mechanisms","volume":"118","author":"Ng","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-08329-4","article-title":"Engineered transfer RNAs for suppression of premature termination codons","volume":"10","author":"Lueck","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"102247","DOI":"10.1016\/j.coph.2022.102247","article-title":"CFTR RNA- and DNA-based therapies","volume":"65","author":"Harrison","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.omtn.2022.04.033","article-title":"Efficient suppression of endogenous CFTR nonsense mutations using anticodon-engineered transfer RNAs","volume":"28","author":"Ko","year":"2022","journal-title":"Mol. Ther.\u2013Nucleic Acids"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Jackson, J.J., Mao, Y., White, T.R., Foye, C., and Oliver, K.E. (2023). Features of CFTR mRNA and implications for therapeutics development. Front. Genet., 14.","DOI":"10.3389\/fgene.2023.1166529"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S1569-1993(09)60072-2","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"8","author":"Burton","year":"2009","journal-title":"J. Cyst. Fibros."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00018-016-2387-7","article-title":"From the endoplasmic reticulum to the plasma membrane: Mechanisms of CFTR folding and trafficking","volume":"74","author":"Farinha","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1128\/MCB.25.12.5242-5252.2005","article-title":"Most F508del-CFTR Is Targeted to Degradation at an Early Folding Checkpoint and Independently of Calnexin","volume":"25","author":"Farinha","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1172\/JCI24898","article-title":"Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening","volume":"115","author":"Pedemonte","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.jcf.2017.08.013","article-title":"Therapeutic approaches to CFTR dysfunction: From discovery to drug development","volume":"17","author":"Li","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e00152","DOI":"10.1002\/prp2.152","article-title":"Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR","volume":"3","author":"Farinha","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2021.12.009","article-title":"Mechanism of CFTR correction by type I folding correctors","volume":"185","author":"Fiedorczuk","year":"2022","journal-title":"Cell"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jcf.2019.12.015","article-title":"Clinical effect of lumacaftor\/ivacaftor in F508del homozygous CF patients with FEV1 \u2265 90% predicted at baseline","volume":"19","author":"Aalbers","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.2147\/DDDT.S153719","article-title":"Lumacaftor-ivacaftor in the treatment of cystic fibrosis: Design, development and place in therapy","volume":"13","author":"Connett","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor\u2013Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: A 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_134","first-page":"192","article-title":"Elexacaftor-Tezacaftor-Ivacaftor: The First Triple-Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapy","volume":"25","author":"Ridley","year":"2020","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Bacalhau, M., Camargo, M., Magalh\u00e3es-Ghiotto, G.A.V., Drumond, S., Castelletti, C.H.M., and Lopes-Pacheco, M. (2023). Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis. Pharmaceuticals, 16.","DOI":"10.3390\/ph16030410"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2100671","DOI":"10.1183\/13993003.00671-2021","article-title":"The rescue of F508del-CFTR by elexacaftor\/tezacaftor\/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor","volume":"59","author":"Becq","year":"2021","journal-title":"Eur. Respir. J."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/17\/9599\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:48:41Z","timestamp":1760111321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/17\/9599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":136,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["ijms25179599"],"URL":"https:\/\/doi.org\/10.3390\/ijms25179599","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,4]]}}}